Atazanavir Is a Competitive Inhibitor of SARS-CoV-2 M<sup>pro</sup>, Impairing Variants Replication In Vitro and In Vivo

Atazanavir Is a Competitive Inhibitor of SARS-CoV-2 M<sup>pro</sup>, Impairing Variants Replication In Vitro and In Vivo

Atazanavir (ATV) has already been considered as a potential repurposing drug to 2019 coronavirus disease (COVID-19); however, there are controversial reports on its mechanism of action and effectiveness as anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Through the pre-clinical ch...

Full description

Bibliographic Details
Main Authors: Otávio Augusto Chaves, Carolina Q. Sacramento, André C. Ferreira, Mayara Mattos, Natalia Fintelman-Rodrigues, Jairo R. Temerozo, Leonardo Vazquez, Douglas Pereira Pinto, Gabriel P. E. da Silveira, Laís Bastos da Fonseca, Heliana Martins Pereira, Aluana Santana Carlos, Joana C. d’Avila, João P. B. Viola, Robson Q. Monteiro, Patrícia T. Bozza, Hugo Caire Castro-Faria-Neto, Thiago Moreno L. Souza
Format: Article
Language:English
Published: MDPI AG 2021-12-01
Series:Pharmaceuticals
Subjects:
SARS-CoV-2
COVID-19
repurposing drugs
atazanavir
protease inhibitor
pharmacokinetics
Online Access:https://www.mdpi.com/1424-8247/15/1/21

Internet

https://www.mdpi.com/1424-8247/15/1/21

Similar Items